Production of Non Viral DNA Vectors

Current Gene Therapy

Volumn 10, Issue 6, 2010, Pages 487-507

  Schleef, Martin ^a   Blaesen, Markus ^a   Schmeer, Marco ^a   Baier, Ruth ^a   Marie, Corinne ^b,c,d,e   Dickson, George ^f   Scherman, Daniel ^b,c,d,e  

^a Dept Process Development   (Germany)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c PSL RESEARCH UNIVERSITY   (France)

^d CNRS   (France)

^e Centre National de la Recherche Scientifique   (France)

^f UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Contract manufacturing; Gene and cell therapy; Minicircle; pFAR; Plasmid DNA; Quality assurance and control; Vaccination; Vector production

Indexed keywords

DNA VACCINE; LIPOPLEX; PLASMID DNA; VIRUS DNA; VIRUS VECTOR;

ARTICLE; BIOLISTIC TRANSFORMATION; BIOSAFETY; BIOTECHNOLOGY; CELL THERAPY; CHROMATOGRAPHY; CLONING VECTOR; DNA IMMUNIZATION; DNA VECTOR; DRUG INDUSTRY; ECHOGRAPHY; ELECTROPORATION; ESCHERICHIA COLI; GENE GUN; GENE THERAPY; GENE TRANSFER; GENE VECTOR; HUMAN; HYDRODYNAMICS BASED TRANSFECTION; JET INJECTION; MAGNETOFECTION; MICELLE; NEEDLE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PLASMID; QUALITY CONTROL; SONOPORATION; STEM CELL TRANSPLANTATION; SYRINGE; TISSUE CULTURE; VIRAL GENE DELIVERY SYSTEM; VIRUS GENE;

ANIMALIA;

EID: 78651330515     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652310793797711     Document Type: Article

References (197)

1. Graham FL, van der Eb AJ. Transformation of rat cells by DNA ofhuman adenovirus 5. Virology 1973; 54: 536-9.
2. Neumann E, Schaefer-Ridder M, Wang Y, Hofschneider PH. Genetransfer into mouse lyoma cells by electroporation in high electricfields. EMBO J 1982; 1: 841-5.
3. Felgner PL, Gadek TR, Holm M, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A 1987; 84: 7413-7.
4. Wolff JA, Williams P, Acsadi G, Jiao S, Jani A, Chong W. Conditionsaffecting direct gene transfer into redent muscle in vivo. Biotechniques 1991; 11: 474-85.
5. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 1997; 15: 617-48.
6. Schmeer M. Electroporative Gene Transfer. In Walther W, Stein US Eds, Methods in molecular biology, gene therapy of cancer. Totowa NJ, Humana Press 2009; 157-165.
7. Plank C, Scherer F, Rudolph C. Localized Nucleic Acid Delivery:A discussion of selected methods. In: Schleef M Ed, DNA Pharmaceuticals:Formulation and Delivery in Gene Therapy, DNA Vaccinationand Immunotherapy. Weinheim, Wiley-VCH 2005; pp. 55-116.
8. Bloquel C, Fabre E, Bureau MF, Scherman D. Plasmid DNA electrotransferfor intracellular and secreted proteins expression: newmethodological developments and applications. J Gene Med 2004; 6: 11-23.
9. Trollet C, Bigey P, Scherman D. Electrotransfection-An Overview. In: Schleef M Ed, DNA Pharmaceuticals: formulation anddelivery in gene therapy, dna vaccination and immunotherapy. Weinheim, Wiley-VCH 2005; pp. 189-218.
10. Mir LM. Electrogenetransfer in clinical applications. In: Schleef MEd, DNA Pharmaceuticals: formulation and delivery in gene therapy, DNA vaccination and immunotherapy. Weinheim, Wiley-VCH 2005; pp. 219-26.
11. Davies LA, Hyde SC, Gill DR. Plasmid inhalation: Delivery to theAirways. In: Schleef M Ed, DNA pharmaceuticals: formulation anddelivery in gene therapy, dna vaccination and immunotherapy. Weinheim, Wiley-VCH 2005; pp. 145-64.
12. Fabre JW. Hydrodynamic Gene Delivery. In: Schleef M Ed, DNAPharmaceuticals: Formulation and Delivery in Gene Therapy, DNAVaccination and Immunotherapy. Weinheim, Wiley-VCH 2005; pp. 165-72.
13. Iwanaga K, Tominaga K, Yamamoto K, et al. Local delivery systemof cytotoxic agents to tumors by focused sonoporation. Cancer Gene Ther 2007; 14: 354-63.
14. Zeira E, Manevitch A, Khatchatouriants A, et al. Femtosecond Infrared Laser-An efficient and safe in vivo gene delievery systemfor prolonged expression. Mol Ther 2003; 8: 342-50.
15. Nishiyama N, Kataoka K. Current state, achievements, and futureprospects of polymeric micelles as nanocarriers for drug and genedeliver. Pharmacol Ther 2006; 112: 630-48.
16. Barron LG, Gagne L, Szoka FC. Lipoplex-mediated gene deliveryto the lung occurs within 60 minutes of intravenous administration. Hum Gene Ther 1999; 10: 1683-94.
17. Koltover I, Salditt T, Rädler JO, Safinya CR. An inverted hexagonalphase of cationic liposome-DNA complexes related to DNA releaseand delivery. Science 1998; 281: 78-81.
18. Newman CMH, Bettinger T. Gene therapy progress and prospects:Ultrasound for gene transfer. Gene Therapy 2007; 14: 465-75
19. Fuller DH, Loudon P, Schmaljohn C. Preclinical and clinical progressof particle-mediated DNA vaccines for infectious diseases. Methods 2006; 40: 86-97.
20. Giese M. DNA-antiviral vaccines: new developments and approaches-a review. Virus Genes 1998; 17: 219-32.
21. Andrianaivo F, Lecocq M, Wattiaux-De Coninck S, Wattiaux R, Jadot M. Hydrodynamics-based transfection of the liver: entranceinto hepatocytes of DNA that causes expression takes place veryearly after injection. J Gen Med 2004; 6: 877-83.
22. Wooddell JO, Zhang CI, Hagstrom G., et al. Evaluation of hydrodynamiclimb vein injections in nonhuman primates. Hum Gene Ther 2010; 21: 829-42.
23. Zhang X, Dong X, Sawyer GJ, Collins L, Fabre JW. Regionalhydrodynamic gene delivery to the rat liver with physiological volumesof DNA solution. J Gen Med 2004; 6: 693-703.
24. Inoue S, Hakamata Y, Kaneko M, Kobayashi E. Gene therapy fororgan grafts using rapid injection of naked DNA: application to therat liver. Transplantation 2004; 77: 997-1003.
25. Walther W, Stein U, Fichtner I, et al. Intratumoral low-volume jetinjectionfor efficient nonviral gene transfer. Mol Biotechnol 2002; 21: 105-15.
26. Steele KE, Stabler K, Vander Zanden L. Cutaneous DNA vaccinationagainst ebola virus by particle bombardment: histopathologyand alteration of CD3-positive dendritic epidermal cells. Vet Pathol 2001; 38: 203-15.
27. Yang Y, Li Q, Ertl HC, Wilson JM. Cellular and humoral immuneresponses to viral antigens create barriers to lung-directed genetherapy with recombinant adenoviruses. J Virol 1995; 69: 2004-15.
28. Ziady AG, Davis PB, Konstan MW. Non-viral gene transfer therapyfor cystic fibrosis. Expert Opin Biol Ther 2003; 3: 449-58.
29. Davies LA, Hyde SC, Gill DR. Plasmid Inhalation: Delivery to theAirways. In Schleef M Ed, Plasmids for therapy and vaccination. Weinheim, Wiley-VCH 2005; pp. 145-64.
30. Schmeer M, Seipp T, Pliquett U, Kakorin S, Neumann E. Mechanismfor the conductivity changes caused by membrane electroporationof CHO cell-pellets. PCCP 2004; 6: 5564-74.
31. Miklavcic D, Semrov D, Mekid H, Mir LM. A validated model ofin vivo electric field distribution in tissues for electrochemotherapyand for DNA electrotransfer for gene therapy. Biochim et Biophys Acta 2000; 1523, 73-83.
32. Mir L, Burauu M, Gehl J, et al. High efficiency gene transfer intoskeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 1999; 96: 4262-7.
33. Bureau, MF, Gehl J, Deleuze V, Mir LM, Scherman D. Importanceof association between permeabilization and electrophoretic forcesfor intramuscular DNA electrotransfer. Biochim Biophys Acta 2002; 1474: 353-9.
34. Trollet C, Bloquel C, Scherman D, Bigey P. Electrotransfer intoskeletal muscle for protein expression. Curr Gene Ther 2006; 5: 561-78.
35. Scherer F, Anton M, Schillinger U, et al. Magnetofection: enhancingand targeting gene delivery by magnetic force in vitro and invivo. Gene Ther 2002; 9: 102-9.
36. Huettinger C, Hirschberger J, Jahnke A, et al. Neoadjuvant genedelivery of feline granulocyte-macrophage colony-stimulating factorusing magnetofection for the treatment of feline fibrosarcomas:a phase I trial. J Gene Med 2008; 10: 655-67.
37. Jahnke A, Hirschberger J, Fischer C, et al. Intra-tumoral Gene Delivery of feIL-2, feIFN-gamma and feGM-CSF using Magnetofectionas a Neoadjuvant Treatment Option for Feline Fibrosarcomas:A Phase-I Study. J Vet Med A Physiol Pathol Clin Med 2007; 10: 599-606.
38. Li YS, Davidson E, Reid CN, McHale AP. Optimising ultrasoundmediatedgene transfer (sonoporation) in vitro and prolonged expressionof a transgene in vivo: Potential applications for gene therapyof cancer. Cancer Lett 2008; 273: 156-62.
39. Smith AE. Viral Vectors in Gene Therapy. Annu Rev Microbiol 1995; 49: 807-38.
40. Recchia A, Perani L, Sartori D, Olgiati C, Mavilio F. Site-Specific Integration of Functional Transgenes into the Human Genome byAdeno/AAV Hybrid Vectors. Mol Ther 2004; 10: 660-70.
41. Alton EWFW, Middleton PG, Caplen NJ, et al. Non-invasiveliposome-mediated gene delivery can correct the ion transport defectin cystic fibrosis mutant mice. Nat Genet 1993; 5: 135-42.
42. Caplen NJ, Gao X, Hayes P, et al. Gene therapy for cystic fibrosisin humans by liposome-mediated DNA transfer: U. K. regulatoryprocess and production of resources. Gene Ther 1994; 1: 139-47.
43. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiencydue to adenosine deaminase deficiency. N Engl J Med 2009; 360: 447-58.
44. Fischer A, Cavazzano-Calvo M. Gene therapy of inherited diseases. Lancet 2008; 371: 2044-7.
45. Miller JW. Preliminary results of gene therapy for retinal degeneration. N Engl J Med 2008; 358: 2282-4.
46. Cartier N, Hacein-Bey-Abina S, Bartholomae CC. Hematopoieticstem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326: 818-23.
47. Naldini L. A Comeback for gene therapy. Science 2009; 326: 805-6.
48. Michel ML, Davis HL, Schleef M, Mancini M, Tiollais P, Whalen RG. DNA-mediated immunization to the hepatitis B surface antigenin mice: Aspects of the humoral response mimic hepatitis B viralinfection in humans. Proc Natl Acad Sci USA 1995; 92: 5307-11.
49. Major ME, Vitvitski L, Mink MA, et al. DNA based immunisationusing chimeric vectors for the induction of immune responsesagainst the hepatitis C virus nucleocapsid. J Virol 1995; 69: 5798-805.
50. Le Borgne S, Mancini M, Le Grand R, et al. In vivo induction ofspecific cytotoxic T lymphocytes in mice and rhesus macaquesimmunized with DNA vector encoding HIV epitope fused withhepatitis B surface antigen. Virology 1998; 240: 304-15.
51. Gregoriadis G. Genetic vaccines: strategies for optimization. Pharm Res 1998; 15: 661-70.
52. Schirmbeck R, van Kampen J, Metzger K, et al. DNA-based vaccinationwith polycistronic expression plasmids. In Lowrie DB, Whalen RG Eds, DNA Vaccines: Methods and Protocols. Totowa NJ, Humana Press 1999; pp. 313-22.
53. Kanellos T, Sylvester ID, Colin, RH, Russelk PH. DNA is as effectiveas protein at inducing antibody in fish. Vaccine 1999; 17: 965-72.
54. Wahren B, Liu M. DNA Vaccines-An Overview. In: Schleef MEd, DNA pharmaceuticals: formulation and delivery in gene therapy, DNA vaccination and immunotherapy. Weinheim, Wiley-VCH 2005; pp. 1-6.
55. Schwarz B, Kempf T, Schillinger U, et al. Cloning of the felinecytokines IL-2, IFNy and GM-CSF for an adjuvant nonviral genetherapyof feline fibrosarcoma. Kleintierpraxis 2007; 52: 569-78.
56. Schleef M, Ed. Plasmids for therapy and vaccination. Wiley-VCH, Weinheim 2001.
57. Schleef M, Ed. DNA pharmaceuticals. Wiley-VCH, Weinheim 2005.
58. CBER. Points to consider on plasmid DNA vaccines for preventiveinfectious disease indications. (HFM-630). Center for Biologics Evaluation and Research, FDA, Rockville MD 1996.
59. CBER. Guidance for industry: guidance for human somatic celltherapy and gene therapy. Center for Biologics Evaluation and Research, FDA, Rockville MD 1998.
60. Meager A, Robertson JS. Regulatory and standardization issues forDNA and vectored vaccines. Curr Res Mol Ther 1999; 1: 262-5.
61. Robertson J, Griffiths E. WHO guidelines for assuring the qualityof DNA vaccines. Biologicals 1998; 26: 205-12.
62. Kneuer CM. DNA as a Pharmaceutical-regulatory aspects. In:Schleef M, Ed, DNA pharmaceuticals: formulation and delivery ingene therapy, DNA vaccination and immunotherapy. Weinheim, Wiley-VCH 2005; pp. 7-22.
63. King NMP, Cohen-Haguenauer O. En route to ethical recommendationsfor gene transfer clinical trials. Mol Ther 2008; 16: 432-8.
64. Grimm D, Kern A, Rittner K, Kleinschmidt JA. Novel tools forproduction and purification of recombinant adenoassociated virusvectors. Hum Gene Ther 1998; 9: 2745-60.
65. Kern A, Schmidt K, Leder C, et al. Identification of a heparinbindingmotif on adeno-associated virus type 2 capsids. J Virol 2003; 77: 11072-81.
66. Chadeuf G, Ciron C, Moullier P, Salvetti A. Evidence for encapsidationof prokaryotic sequences during recombinant adenoassociatedvirus production and their in vivo persistence after vectordelivery. Mol Ther 2005; 12: 744-53.
67. Schleef M. Issues of large-scale plasmid manufacturing. In Rehm HJ, Reed G, Pühler A, Stadler P Eds, Biotechnology Vol. 5a: Recombinantproteins, monoclonal antibodies and therapeutic genes. Weinheim, Wiley-VCH 1999; pp. 443-70.
68. Hoare M, Levy MS, Bracewell DG, et al. Bioprocess engineeringissues that would be face in producing a DNA vaccine at up to 100m3 fermentation scale for an influenza pandemic. Biotechnol Prog 2005; 21: 1577-92.
69. Urthaler J, Buchinger W, Necina R. Improved downstream processfor the production of plasmid DNA for gene therapy. Act Biochim Polonica 2005; 52: 703-11.
70. Schleef M, Schmidt T, Flaschel E. Plasmid DNA for pharmaceuticalapplications. Dev Biol 2000; 104: 25-31.
71. Voss C, Schmidt T, Schleef M. From bulk to delivery: plasmidmanufacturing and storage. In: Schleef M Ed, DNA pharmaceuticals:formulation and delivery in gene therapy, DNA vaccinationand immunotherapy. Weinheim, Wiley-VCH 2005; pp. 23-42.
72. Lederberg J. Cell genetics and hereditary symbiosis. Physiol Rev 1952; 32: 403-30.
73. Helinski D. Bacterial plasmids: autonomous replication and vehiclesfor gene cloning. Crit Rev Biochem 1979; 7: 83-101.
74. Summers DK. The Biology of Plasmids. Blackwell Science, Oxford 1996.
75. Schumann W. The biology of plasmids. In Schleef M Ed, Plasmidsfor therapy and vaccination. Weinheim, Wiley-VCH 2001; pp. 1-43.
76. Davis BD, Dulbecco R, Eisen HN, Ginsberg HS Eds. Microbiology. Harper and Row, Philadelphia 1980.
77. Schmidt T, Friehs K, Schleef M, Voss K, Flaschel E. Quantitativeanalysis of plasmid forms by agarose and capillary gel electrophoresis. Analyt Biochem 1999; 274: 235-40.
78. Devlin TM Ed. Textbook of biochemistry with clinical correlations. Wiley-Liss, New York 1997.
79. Maucksch C, Hoffmann F, Schleef M, et al. Transgene expressionof transfected supercoiled plasmid DNA concatemers in mammaliancells. J Gene Med 2009; 11: 444-53.
80. Darquet AM, Cameron B, Wils P, Scherman D, Crouzet J. A newDNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther 1997; 4: 1341-49.
81. Kreiss P, Cameron B, Rangara R, et al. Plasmid DNA size does notaffect the physiological properties of lipoplexes but modulates genetransfer efficiency. Nucleic Acids Res 1999; 27: 3792-98.
82. Voss C, Schmidt T, Schleef M, Friehs K, Flaschel E. Verwendungvon isolierten homogenen Nukleinsäure-Multimeren für die nichtviraleGentherapie oder genetische Impfung. DE 10101761, 2006.
83. Del Solar G, Giraldo R, Ruiz-Echevarria MJ, Espinosa M, Diaz-Orejas R. Replication and control of circular bacterial plasmids. Microbiol Mol Biol Rev 1998; 62: 434-64.
84. Hayes F. The function and Organization of plasmids. In Casali N, Preston A Eds, E. coli Plasmid Vectors. Totowa NJ; Humana Press 2003, pp. 1-17.
85. Preston A. Choosing a Cloning Vector. In Casali N, Preston A Eds, E. coli Plasmid Vectors. Totowa NJ; Humana Press 2003, pp. 19-26.
86. Vieira J, Messing. J (1982) The pUC plasmids, an M13 mp7-derived system for insertion mutagenesis and sequencing with syntheticuniversal primers. Gene 1982; 19: 259-68.
87. Blattner FR, Plunkett G, Bloch CA, et al. The complete genomesequence of Escherichia coli K-12. Science 1997; 277: 1453-74.
88. Tatum EL, Lederberg J. Gene recombination in the bacteriumEscherichia coli. J Bacteriol 1947; 53: 673-84.
89. Casali N. Escherichia coli Host Strains. In Casali N, Preston A Eds, E. coli Plasmid Vectors. Totowa NJ; Humana Press 2003, pp. 27-48.
90. Bochner BR. Global phenotypic characterization of bacteria. FEMSMicrobiol Rev 2009; 33: 191-205.
91. Schleef M, Schmidt T. Animal-free production of ccc-supercoiledplasmids for research and clinical applications. J Gene Med 2004; 6: 45-53.
92. Bridson E. The development, manufacture and control of microbiologicalculture media. Unipath Ltd., Basingstoke 1994.
93. EMEA. Note for guidance on minimising the risk of transmittinganimal spongiform encephalopathy agents via human and veterinarymedicinal products. CPMP/410/01 rev 1, London 2001.
94. Blaesen M, Friehs K, Flaschel E. Recycling of bacterial biomass ina process of L-threonine production by means of a recombinantstrain of Escherichia coli. J Biotechnol 2007; 132: 431-7.
95. Plasmid Factory Gmb H & Co KG. Verfahren zur Behandlung vonBiomasse aus biologischen Prozessen und Verwertung der so entstandenenProdukte. DE 198 05 664 B4 2010
96. Schroeckh V, Hartmann M, Birch-Hirschfeld E, Riesenberg D. Improvement of recombinant gene-expression in Escherichia colifor glucose-controlled continuous and fed-batch cultures. Appl Microbiol Biotechnol 1992; 36: 487-92.
97. Horn N, Budahazi G, Marquet M. Purification of plasmid DNAduring column chromatography. U. S. Patent 5,707,812, 1998.
98. Wang F, Lee SY. High cell density culture of metabolically engineeredEscherichia coli for the production of Poly(3-hydroxybutyrate) in a defined medium. Biotechnol Bioeng 1998; 58: 325-8.
99. Lee SY, Chang HN. (1994) High cell density cultivation of Escherichiacoli using sucrose as a carbon source. Biotechnol Lett 1994; 15: 971-4.
100. Nakano K, Rischke M, Sato S, Märkl H. Influence of acetic acid onthe growth of Escherichia coli K12 during high-cell-density cultivationin a dialysis reactor. Appl Microbiol Biotechnol 1997; 48: 597--601.
101. Schmidt T, Schleef M, Friehs K, Flaschel E. Hochzelldichtefermentationzur Gewinnung von Plasmid-DNA für Gentherapie undgenetische Impfung. BIOforum 1999; 22: 174-7.
102. Macaloney G, Hall JW, Rollins MJ, et al. The utility and performanceof near-infrared spectroscopy in simultaneous monitoringmultiple components in a high cell density recombinant Escherichiacoli production process. Bioproc Eng 1997 17: 157-67.
103. Paalme T, Tiisma K, Kahru A, Vanatalu K, Vilu R. Glucoselimitedfed-batch cultivation of Escherichia coli with computercontrolledfixed growth rate. Biotechnol Bioeng 1990; 35: 312-9.
104. Reinikainen P, Korpela K, Nissinen V, Olkku J, Söderlund H, Markkanen P. Escherichia coli plasmid production in fermenter. Biotechnol Bioeng 1989; 33: 386-93.
105. Lahijani R, Hulley G, Soriano G, Horn NA, Marquet M. High-yieldproduction of pBR322-derived plasmids intended for human genetherapy by employing a temperature-controllable point mutation. Hum Gene Ther 1996; 7: 1971-80.
106. Voss C, Schmidt T, Schleef M, Friehs K, Flaschel E. Effect ofammonium chloride on plasmid DNA production in high cell densitybatch culture for biopharmaceutical use. J Chem Technol Biotechnol 2004; 79: 57-62.
107. Colpan M, Schorr J, Moritz P. Process for producing endotoxinfreeor endotoxin-poor nucleic acids and/or oligonucleotides forgene therapy. WO 95/21177, 1995.
108. Bussey L, Adamson R, Atchley A. Methods for purifying nucleicacids. WO 98/05673, 1998.
109. Schorr J, Moritz P, Schleef M. Production of plasmid DNA inindustrial quantities according to cGMP guidelines. In: Lowrie DB, Whalen RG Eds, DNA Vaccines: Methods and Protocols. Totowa NJ, Humana Press 1999; pp. 11-21.
110. Green AP. Purification of supercoiled plasmid In: Lowrie DB, Whalen RG Eds, DNA Vaccines: Methods and Protocols. Totowa NJ, Humana Press 1999; pp. 1-9.
111. Chen Z, Ruffner D. Compositions and methods for rapid isolationof plasmid DNA. WO 98/16653, 1998.
112. Murphy JC, Wibbenmeyer JA, Fax GE, Willson RC. Purificationof plasmid DNA using selective precipitation by compactionagents. Nature Biotchnol 1999; 17: 822-3.
113. Stadler J, Lemmens R, Nyhammar T. Plasmid DNA purification. JGene Med 2004; 6: 54-66.
114. Lee AL, Sagar S. A method for large scale plasmid purification. WO 96/36706, 1999
115. Schumacher I, Freitag R, Hilbrig F. Method for treating biomassfor producing cell lysate containing plasmid DNA. WO 02/057446A2, 2002.
116. Hebel H, Ramakrishnan S, Gonzales H, Darneli J. Devives andmethods for biomaterial production. WO 2004/108260, 2004.
117. Voß C, Schmidt T, Schleef M. From bulk to delivery: plasmidmanufacturing and storage. In: Schleef M, Ed, DNA pharmaceuticals:formulation and delivery in gene therapy, DNA vaccinationand immunotherapy. Weinheim, Wiley-VCH 2005; pp. 23-42.
118. Thatcher DR, Hitchcock AG, Hanak JA, Varley DL. Method ofplasmid DNA production and purification. WO 97/29190, 1997.
119. Ferreira GNM, Prazeres DMF, Cabral JMS, Schleef M. Plasmidmanufacturing-an overview. In Schleef M Ed, Plasmids for therapyand vaccination. Weinheim, Wiley-VCH 2001; pp. 193-236.
120. Lemmens R, Olsson U, Nyhammar T, Stadler J. Supercoiled plasmidDNA: selective purification by thiophilic/aromatic adsorption. J Chromatogr B 2003; 784: 291-300.
121. Strancar A, Podgornik A, Barut M, Necina R. Short monlithiccolumns as stationary phases for biochromatography. Adv Biochem Eng Biotechnol 2002; 76: 49-85.
122. Southern EM. Detection of specific sequences among DNA fragmentsseparated by gel electrophoresis. J Mol Biol 1975; 98: 503-17.
123. Smith GJ, Helf M, Nesbet C, Betita HA, Meek J, Ferre F. Fast andaccurate method for quantitating E. coli host-cell DNA contaminationin plasmid DNA preparations. Bio Techniques 1999; 26: 518-26.
124. Hyde SC, Pringle IA, Abdullah S, et al. Cp G-free plasmids conferreduced inflammation and sustained pulmonary gene expression. Nature Biotech 2008; 26: 549-51.
125. Levy MS, Collins IJ, Tsai JT, Shamlou PA, Ward JM, Dunnill P. Removal of contaminant nucleic acids by nitrocellulose filtrationduring pharmaceutical-grade plasmid DNA processing. J Biotech 2000; 76: 197-205.
126. Wils P, Escriou V, Warnery A, et al. Efficient purification of plasmidDNA for gene transfer using triple-helix affinity chromatography. Gene Therapy 1997; 4: 323-30.
127. Gonin P, Gaillard C. Gene transfer vector biodistribution: pivotalsafety studies in clinical gene therapy development. Gene Ther 2004; 11: 98-108.
128. Walther W, Minow T, Martin R, Fichtner I, Schlag PM, Stein U. Uptake, Biodistribution, and Time Course of Naked Plasmid DNATrafficking After Intratumoral In Vivo Jet Injection. Hum Gene Ther 2006; 17: 611-24.
129. Wolff JA, Williams P, Acsadi G, Jiao S, Jani A, Chong W. Conditionsaffecting direct gene transfer into redent muscle in vivo. Biotechniques 1991; 11: 474-85.
130. Vogel FR, Sarver H. Nucleic acid vaccines. Clin Microbiol Rev 1995; 8: 406-10.
131. Donnelly JJ, Ulmer JB, Liu M. DNA Vaccines. Life Sci 1997; 60: 163-72.
132. Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trialsworldwide to 2007-an update. J Gene Med 2007; 9: 833-42.
133. Jain KK. Vectors for gene therapy: Current status and future prospects. PJB Publications Ltd, London 1996.
134. Bio World. Entstehungsgeschichte eines neuen Medikamentes. Bio World 1999; 2: 31-4.
135. Buckland BC. The process development challenge for a new vaccine. Nature Med 2005; 11: 16-9.
136. Schleef M, Baier R, Walther W, Michel ML, Schmeer M. Long-Term stability studa and topology analysis of plasmid DNA by capillarygel electrophoresis. Bio Process Int 2006; 4: 38-40.
137. Yew NS, Zhao H, Wu IH, et al. Reduced Inflammatory Responseto Plasmid DNA Vectors by Elimination and Inhibibition of Immunostimulatory Cp G Motifs. Mol Ther 2000; 1: 255-62.
138. Krieg AM, Yi A, Matson S, et al. Cp G motifs in bacterial DNAtrigger direct B-cell activation. Nature 1995; 374: 546-9.
139. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizesbacterial DNA. Nature 2000; 408: 740-5.
140. Klinman DM. Immunotherapeutic uses of Cp G oligodeoxynucleotides. Nature Rev 2004; 4: 1-10.
141. Braun R, Babiuk LA, Little van den Hurk SV. Compatibility ofplasmids expressing different antigens in a single DNA vaccineformulation. J Gen Virol 1998; 79: 2965-70.
142. Schneider J, Gilbert SC, Hill A. pSG. MEPf TRAP-a first generationmalaria DNA vaccine vector. In Schleef M Ed, Plasmids fortherapy and vaccination. Weinheim, Wiley-VCH 2001; pp. 103-17.
143. Schmidt T, Friehs K, Flaschel E. Structures of plasmid DNA. In Schleef M Ed, Plasmids for therapy and vaccination. Weinheim, Wiley-VCH 2001; pp. 29-43.
144. EMA. Scientific guidelines for human medicinal products. www.emea.europa.eu/htms/human/humanguidelines/background.htm, 2008.
145. WHO. World Health Organsization expert committee on biologicalstandardization 56th report, WHO technical series 941, 2007.
146. De Leys RJ, Jackson DA. Dye titrations of covalently closed supercoiledDNA analysed by agarose gel electrophoresis. Biochem Biophys Res Commun 1975; 69: 446-54.
147. Johnson PH, Grossmann, LI. Electrophoresis of DNA in agarosegels. Optimizing separations of conformationsl isomers of doubleandsingle-stranded DNAs. Biochemistry 1977; 16: 4217-25.
148. Meyers JA, Sanchez D, Elwell LP, Falkow S. Simple agarose gelelectrophoretic method for the identification and characterization ofplasmid deoxyribonucleic acid. J Bacteriol 1976; 127: 1529-37.
149. Pulleyblank, DE, Morgan AR. The sense of naturally occuringsuperhelices and the unwinding angle of intercalated ethidium. JMol Biol 1975; 91: 1-13.
150. Tse YC, Wang JC. E. coli and M. luteus DNA topoisomerase I cancatalyze catenation or decatenation of double-stranded rings. Cell 1980; 22: 269-76.
151. Martin R. Gel Electrophoresis: Nucleic Acids. Bios Scientific Publishers, London 1996.
152. Sinden RR. DNA structure and function. Academic Press, San Diego CA 1994.
153. Oliver SG, Ward JM. A dictionary of genetic engineering. Cambridge University Press, Cambridge 1985.
154. Serwer P, Allen JA. Conformation of double-stranded DNA duringagarose gel electrophoresis: Fractionation of linear and circularmolecules with molecular weights between 3*106 and 25*106. Biochemistry 1984; 23: 922-7.
155. Garner MM, Chrambach A. Resolution of circular, nicked circularand linear DNA, 4 kb in length, by electrophoresis in polyacrylamidesolutions. Electrophoresis 1992; 13: 176-8.
156. Courtney BC, Williams KC, Bing QA, Schlager J. Capillary gelelectrophoresis as a method to determine ligation efficency. Anal Biochem 1995; 228: 281-6.
157. Nackerdien Z, Morris S, Choquette S, Ramos B, Atha D. Analysisof laser-induced plasmid DNA photolysis by capillary electrophoresis. J Chromatogr B 1996; 683: 91-6.
158. Hammond RW, Oana H, Schwinefus JJ, Bonadio J, Levy RJ, Morris MD. Capillary electrophoresis of supercoiled and linear DNA indilute hydroxyethyl cellulose solution. Anal Chem 1997; 69: 1192-6.
159. Schmidt T, Friehs K, Flaschel E. Rapid determination of plasmidcopy number. J Biotechnol 1996; 49: 219-29.
160. Somia N, Verma IM. Gene therapy: Trials and tribulations. Nat Rev Genet 2000; 1: 91-9.
161. Li Z, Düllmann J, Schiedlmeier B, et al. Murine leukemia inducedby retroviral gene making. Science 2002; 296: 497.
162. Flotte TR. Gene therapy progress and prospects: recombinantadeno-associated virus (rAAV) vectors. Gene Ther 2004; 11: 805-11.
163. Zaiss AK, Muruve DA. Immunity to adeno-associated virus vectorsin animals and humans: a continued challenge. Gene Ther 2008; 15: 808-16.
164. Mairhofer J, Pfaffenzeller I, Merz D, Grabherr R. A novel antibioticfree plasmid selection system: Advances in safe and efficientDNA therapy. Biotechnol J 2008; 3: 83-9.
165. Mir LM, Bureau MF, Gehl J, et al. High-efficiency gene transferinto skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 1999; 96: 4262-7.
166. Krieg AM, Yi AK, Matson S, et al. Cp G motifs in bacterial DNAtrigger direct B-cell activation. Nature 1995; 374: 546-9.
167. Kleina LG, Masson J-M, Normanly J, Abelson J, Miller JH. Constructionof Escherichia coli amber suppressor tRNA genes. II. Synthesis of additional tRNA genes and improvement of suppressorefficiency. J Mol Biol 1990; 213: 705-17.
168. Michaels ML, Kim CW, Mattews DA, Miller JH. Escherichia colithymidylate synthase: amino acid substitutions by suppression ofamber nonsense mutations. Proc Natl Acad Sci USA 1990; 87: 3957-61.
169. Cranenburgh RM, Hanak JA, Williams SG, Sherratt DJ. Escherichiacoli strains that allow antibiotic-free plasmid selectionand maintenance by repressor titration. Nucleic Acids Res 2001; 29: 2120-4.
170. Mairhofer J, Cserjan-Puschmann M, Striedner G, Nöbauer K, Razzazi-Fazeli E, Grabherr R. Marker-free plasmids for gene therapeuticapplications-Lack of antibiotic resistance gene substantiallyimproves the manufacturing process. J Biotechnol 2010; 146: 130-7.
171. Bigger BW, Tolmachov O, Collomber JM, Fragkos M, Palaszewski I, Coutelle C. An araC-controlled bacterial cre expression system toproduce DNA minicircle vectors for nuclear and mitochondrialgene therapy. J Biol Chem 2001; 276: 23018-27.
172. Chen ZY, He CY, Ehrhardt A, Kay MA. Minicircle DNA vectorsdevoid of bacterial DNA result in persistent and high-level transgeneexpression in vivo. Mol Ther 2003; 8: 495-500.
173. Darquet AM, Cameron B, Wils P, Scherman D, Crouzet J. A newDNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther 1997; 4: 1341-9.
174. Jechlinger W, Azimpour Tabrizi T, Lubitz W, Mayrhofer P. Minicircle DNA immobilized in bacterial ghosts: in vivo productionof safe non-viral DNA delivery vehicles. J Mol Microbiol Biotechnol 2004; 8: 222-31.
175. Nehlsen K, Broll S, Bode J. Replicating minicircles: generation ofnonviral episomes for the efficient modification of dividing cells. Gene Ther Mol Biol 2006; 10: 233-44.
176. Sadowski P. Site-specific recombinases: changing partners anddoing the twist. J Bacteriol 1986; 165: 341-7.
177. Gilbertson L. Cre-lox recombination: creative tools for plant biotechnology. Trends Biotechnol 2003; 21: 550-5.
178. Kreiss P, Cameron B, Darquet AM, Scherman D, Crouzet J. Productionof a new DNA vehicle for gene transfer using site-specificrecombination. Appl Microbiol Biotechnol 1998; 49: 560-7.
179. Thorpe HM, Smith MC. In vitro site-specific integration of bacteriophageDNA catalyzed by a recombinase of the resolvase/invertase family. Proc Natl Acad Sci USA 1998; 95: 5505-10.
180. Thorpe HM, Wilson SE, Smith MC. Control of directionality in thesite-specific recombination system of the Streptomyces phagephiC31. Mol Microbiol 2000; 38: 232-41.
181. Eberl L, Kristensen CS, Givskov M, Grohmann E, Gerlitz M, Schwab H. Analysis of the multimer resolution system encoded bythe parCBA operon of broad-host-range plasmid RP4. Mol Microbiol 1994; 12: 131-41.
182. Smith MC, Thorpe HM. Diversity in the serine recombinases. Mol Microbiol 2002; 44: 299-307.
183. Thomson JG, Ow DW. Sitespecific recombination systems for thegenetic manipulation of eukaryotic genomes. Genesis 2006; 44: 465-76.
184. Darquet AM, Rangara R, Kreiss P, et al. Minicircle: animprovedDNA molecule for in vitro and in vivo gene transfer. Gene Ther 1999; 6: 209-18.
185. Kreiss P, Cameron B, Rangara R, et al. Plasmid DNA size does notaffect the physicochemical properties of lipoplexes but modulatesgene. Nucleic Acids Res 1999; 19: 3792-8.
186. Mayrhofer, P., Blaesen, M., Schleef, M., and Jechlinger, W.:Minicircle-DNA production by site specific recombination and protein-DNA interaction chromatography. J Gene Med 2008; 10: 1253-69.
187. Chen ZY, He CY, Kay MA. Improved production and purificationof minicircle DNA vector free of plasmid bacterial sequences andcapable of persistent transgene expression in vivo. Hum Gene Ther 2005; 16: 126-31.
188. Baiker A, Maercker C, Piechaczek C, et al. Mitotic stability of anepisomal vector containing a human scaffold/matrix-attached regionis provided by association with nuclear matrix. Nat Cell Biol 2000; 2: 182-4.
189. Lipps HJ, Jenke ACW, Nehlsen K, Scinteie MF, Stehle IM, Bode J. Chromosome-based vectors for gene therapy. Gene 2003; 304: 23-33.
190. Schaarschmidt D, Baltin J, Stehle IM, Lipps HJ, Knipers R. Anepisomal mammalian replicon: sequence-independent binding ofthe origin recognition complex. EMBO J 2004; 23: 191-201.
191. Nehlsen K, Broll S, Bode J. Replicating Minicircles: Generation ofnonviral episomes for the efficient modification of dividing cells. Gene Ther Mol Biol 2006; 10: 233-44.
192. Chen ZY, He CY, Kay MA. Improved production and purificationpf minicircle DNA vector free of plasmid bacterial sequences andcapable of persistent transgene expression in vivo. Hum Gene Ther 2005; 16: 126-31.
193. Jacobs F, Snoeys J, Feng Y, et al. Direct comparison of hepatocytespecificexpression cassettes following adenoviral and nonviral hydrodynamicgene transfer. Gene Ther 2008; 15: 594-603.
194. Broll S, Oumard A, Hahn K, Schambach A, Bode J. Minicircleperformance depending on S/MAR-nuclear matrix interactions. JMol Biol 2009; 395: 950-65.
195. Elfinger M, Üzgün S, Rudolph C. Nanocarriers for gene delivery-polymer structure, targeting ligands and controlled-release devices. Curr Nanosci 2008; 4: 322-53.
196. Barteau B, Chevre R, Letrou-Bonneval E, Labas R, Lambert O, Pitard B. Physicochemical parameters of non-viral vectors thatgovern transfection efficiency. Curr Gene Ther 2008; 8: 313-23.
197. Favard C, Dean DS, Rols MP. Electrotransfer as a non viral methodof gene delivery. Curr Gene Ther 2007; 7: 67-77.